Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 13Phase 1 9Phase 1/2 5Phase 2/3 3Phase NA 2Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 4Recruiting 3Suspended 1Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Osteosarcoma 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Gemcitabine 12Dexamethasone 12Magnetic Resonance Spectroscopy 10Bevacizumab 10venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Docetaxel 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7130-nm albumin-bound paclitaxel 7Methotrexate 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Platinum × Clear all
NCT05691478 2026-05-27

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

NCT01810913 2026-05-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
613 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡